Horizon Pharma revenues up 49%; Non-GAAP EPS up 59% in Q2; updates guidance

• Horizon Pharma (NASDAQ:HZNP) Q2 results: Revenues: $257.4M (+49.0%); Operating Income: $31.5M (-194.9%); Net Income: $15M (-52.8%); EPS: $0.09 (-55.0%); Non-GAAP EPS: $0.62 (+59.0%); Quick Assets: $424.5M (-50.6%); CF Ops: $47.3M (+13.7%).
• 2016 Guidance: Net Sales: $1.025B - 1.050B; Adjusted EBITDA: $495M - 510M.